JP Morgan Chase’s Northwest Biotherapeutics NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
– Sell
-1,726
Closed -$1K – 5343
2016
Q3
$1K Sell
1,726
-8
-0.5% -$4 ﹤0.01% 4502
2016
Q2
$1K Buy
+1,734
New +$1.85K ﹤0.01% 4742
2016
Q1
– Sell
-1,683
Closed -$5K – 5287
2015
Q4
$5K Buy
+1,683
New +$8.09K ﹤0.01% 4377
2015
Q2
– Sell
-38,630
Closed -$285K – 4388
2015
Q1
$285K Buy
+38,630
New +$260K ﹤0.01% 3725
2014
Q2
– Sell
-39,199
Closed -$284K – 3776
2014
Q1
$284K Buy
+39,199
New +$232K ﹤0.01% 3312

Other funds holding NWBO

JP Morgan Chase's NWBO Position: Q4 2016 in Review

JP Morgan Chase sold out of Northwest Biotherapeutics (NWBO) in Q4 2016, closing a stake of 1,726 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in NWBO in Q1 2014 and held it in 5 quarters. The position peaked at $285K in Q1 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • JP Morgan Chase reported no remaining Northwest Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • JP Morgan Chase sold 1,726 Northwest Biotherapeutics shares in Q4 2016, an estimated $1K.
  • JP Morgan Chase first reported a position in Northwest Biotherapeutics in Q1 2014 and held it in 5 quarters.
  • JP Morgan Chase's Northwest Biotherapeutics position peaked at $285K in Q1 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics as of Q4 2016.

Based on JP Morgan Chase's 13F filing for Q4 2016, filed 6 Feb 2017.